Background. Hepatitis C virus (HCV) testing guidance issued by the Centers for Disease Control and Prevention in 1998 recommends HCV antibody (anti-HCV) testing for persons with specified risk factors. The purpose of this study was to determine the prevalence and predictors of anti-HCV positivity among primary care outpatients and estimate the proportion of unidentified anti-HCV-positive (anti-HCV + ) persons using risk-based testing.
Hepatitis C virus (HCV) infection is an urgent health problem, with an estimated 4 million persons ever infected and approximately 3 million chronically infected in the United States [1, 2] . It is estimated that 45%-60% of adults with HCV infection will develop cirrhosis over the next 2-5 decades [3, 4] . In 2010, HCV infection was the underlying or contributing cause of >16 500 deaths in the United States [5] . Advances in antiviral therapy have resulted in the potential for dramatic reductions in morbidity and mortality among persons treated for HCV infection [6] [7] [8] [9] , but care and treatment can only be provided to those infected persons who are tested and identified.
In 1998, Centers for Disease Control and Prevention (CDC) recommended routine HCV antibody (anti-HCV) testing for persons with specified risk factors and medical indications including history of injection drug use (IDU), persistently elevated alanine aminotransferase (ALT) levels, blood transfusion or organ transplant before 1992, clotting factor concentrates before 1987, and long-term hemodialysis [10] ; in 1999, the US Public Health Service and the Infectious Diseases Society of America jointly recommended HCV testing for all human immunodeficiency virus (HIV)-infected adults [11] . Several noninterventional studies have since examined the effectiveness of risk-based testing among persons receiving care in clinical settings or persons with access to healthcare; the studies have compared the overall observed anti-HCV prevalence-defined as the number of identified persons divided by the total population of patients (tested and not)-to the expected prevalence as determined by population surveys or modeling [12] [13] [14] [15] . Among patients enrolled in an urban managed care organization, Roblin et al determined that the overall observed anti-HCV prevalence was 0.2% [12] ; using a population of patients enrolled in 4 private healthcare organizations, Spradling et al found an overall observed prevalence of approximately 0.9% [13] ; other researchers have found higher observed prevalence rates ranging from 2.5% to 4.6% among predominantly African American and Hispanic populations receiving routine care in urban primary care settings [14, 15] . Unanimously, the overall observed anti-HCV prevalence in these settings has been described as lower than expected and the proportion of unidentified anti-HCV positive persons has been estimated as ranging from 40% to 85% [12] [13] [14] [15] [16] .
In 2012, CDC augmented the risk factor-and medical indication-based HCV screening strategies by issuing a recommendation to test all persons born during 1945-1965 without prior risk ascertainment [17] . Persons in this cohort account for an estimated three-quarters of all HCV infections and HCVassociated deaths in the United States [18, 19] . In 2013, the US Preventive Services Task Force also revised its recommendations to include this birth cohort based on their review of the available evidence [20] .
This study sought to determine anti-HCV prevalence and factors associated with anti-HCV positivity in a large geographically and demographically diverse cohort of adult primary care outpatients with no previous diagnosis of HCV. We also aimed to estimate the proportion of unidentified anti-HCV-positive (anti-HCV + ) persons within this cohort.
METHODS

Study Design
We conducted a cross-sectional analysis using electronic medical record (EMR) data of patients from the Birth Cohort Evaluation to Advance Screening and Testing for HCV (BEST-C), a multisite retrospective cohort study.
Study Setting and Participants
Participants in BEST-C included all newly enrolled patients aged ≥18 years with no previous diagnosis of anti - Only new patients with a first-time encounter through primary care were included in this study based on the understanding that health screening is most likely to occur for new patients [16] ; patients with documentation of HCV diagnosis at the time of first encounter were excluded. Data on patient demographics, clinical characteristics, and anti-HCV testing were collected at each patient's first visit and at successive encounters during the study period to create an encounter-level dataset. Encounter-level data were summarized to create a patient-level dataset. The current analysis is based on 209 076 patients. We calculated the period of observation (in months) as the date of last visit minus date of first visit; patients with a single visit were coded as observed for 1 month.
Outcome Variables
The main outcome measure for this analysis was anti-HCV positivity. We defined anti-HCV positivity as a positive test result for antibodies to HCV by enzyme-linked immunoassay at any visit during the study period.
Independent Variables
Independent variables previously associated with anti-HCV positivity were selected for this analysis [12, 14, 21] . Demographic variables examined included birth year, race/ethnicity, sex, marital status, and annual census tract-level income. Census tract income was used as a proxy for household income, which was unavailable. Birth year was dichotomized as born during or born outside the 1945-1965 birth cohort. Race/ethnicity was categorized as white, black, Hispanic, Asian, or other. Sex was classified as male or female. Marital status was categorized as married, divorced/separated/widowed, or never married. Income was categorized as <$30 000, $30 000-$49 999, $50 000-$69 000, $70 000-$99 000, and ≥$100 000. We also examined the following clinical variables: history of IDU, elevated ALT, hemophilia, HIV infection, and total number of patient encounters with health system during the study period. History of IDU was defined as having an International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) diagnosis code for IDU (292, 304, 305, 969.7, 970.8, 965 .01) documented in the EMR at any time during the study period. This search strategy was augmented by text query of the EMR for evidence of IDU. Patients were coded as having a history of elevated ALT if a laboratory record for ALT test with abnormal result was associated with the EMR at any visit during the study period. Cutoff levels used to establish elevated ALT were sex-and site-specific. Hemophilia (ICD-9-CM 286.52, 286.5) and HIV infection (ICD-9-CM V08, 042) were similarly identified. Identification of HIV infection was enhanced by search of text notes in the EMR. Data regarding other known covariates of anti-HCV positivity such as hemodialysis and blood transfusion before 1992 were not included in this analysis due to lack of consistency in data collection across sites. History of IDU, hemophilia, HIV infection, and elevated ALT were coded as yes or no/unknown.
Statistical Analysis
Multiple Imputation of Missing Data Overall, about 51.0% of all patients had missing data for at least 1 demographic variable. To maintain statistical power and to avoid potential bias in statistical estimates [22] , we used IVEware version 0.1 to replace missing values by multiple imputation using the method of sequential regression multivariate imputation [23] . Imputed datasets were individually analyzed with standard software and summarized per the Rubin method with appropriate adjustment for degrees of freedom [24] (Supplementary Appendix).
Statistical Estimates
Statistical significance for all tests was set at a 2-tailed P value of .05. We calculated proportions to describe the characteristics of the overall study population as well as the subpopulation of patients who were tested for anti-HCV at any time during the study period. Overall observed prevalence [13, 14] was estimated by dividing the total number of anti-HCV + persons by the total number of all participants (tested or not). This approach assumes that because testing is driven by risk factors and medical conditions, patients who are not tested are more likely to be negative for anti-HCV. Expected prevalence was estimated by extending multiple imputation to anti-HCV status for patients who were not tested (Supplementary Appendix). Specifically, imputed anti-HCV values were assigned to each patient who was not tested, fully conditional on all data observed for that patient. The proportion of unidentified anti-HCV + persons was subsequently estimated as the difference between expected prevalence and observed prevalence divided by expected prevalence in the study population. We performed sensitivity analyses to assess effect of duration of follow-up on this estimate. Among patients who were tested for anti-HCV during the 6-year study period, we calculated anti-HCV positivity by dividing the total number of anti-HCV + patients by the total number of tested patients. To account for clustering of patients within study sites, we used univariate generalized linear mixed models to test for differences in anti-HCV positivity by patient characteristics [25] . We also fit a prespecified multilevel multiple logistic regression model adjusting for the random effect of site to identify independent correlates of anti-HCV positivity among patients tested. 
RESULTS
Characteristics of Study Population
A total of 209 076 patients were included in the analysis. The median length of observation was 5 months with an interquartile range of 1 to 23. A summary of the demographic and clinical characteristics of patients is presented in Table 1 .
Observed and Expected Prevalence Estimates
The overall observed prevalence (ie, the rate of anti-HCV identification) among all patients was 0.53% (n = 1115/209 076). Using multiply imputed anti-HCV values for patients who were not tested, we estimated the corresponding expected prevalence to be 2.87% (n = 6005/209 076), with a range of 0.84% to 4.34% across the 4 sites. We further estimated that 81.5% (n = 4890/ 6005) of anti-HCV + persons were not identified using riskbased testing strategy (Table 2) . Upon restricting the analytic data to new patients who had been enrolled in the health system for at least 12 months (median follow-up = 30 months), the proportion of unidentified anti-HCV patients was estimated at 80%; a restricted analysis of new patients who were enrolled for at least 24 months (median follow-up = 40 months) yielded a similar result (79%). Among patients born between 1945 and 1965, the estimated proportion of unidentified anti-HCV + persons was 76% (ie, observed prevalence = 1.2%; expected prevalence = 4.9%).
Positivity Among Patients Tested
Among patients who were tested for anti-HCV, 6.4% (n = 1115 /17 464) were positive ( (Table 4) . Hemophilia and HIV-positive status were not significantly associated with anti-HCV positivity. Sensitivity analysis using complete cases indicated that point estimates were comparable to results from the imputed data, imputation Abbreviations: ALT, alanine aminotransferase; CI, confidence interval; HIV, human immunodeficiency virus; OR, odds ratio. a Adjusted for random effect of site and the following fixed effects: birth year, sex, race, marital status, injection drug use, elevated ALT, hemophilia, HIV status, and total number of encounters with healthcare system. b Missing values for sex, race/ethnicity, and marital status were multiply imputed.
* P < .001.
** P values were between <.001 and <.01. *** P values were between <.01 and <.05.
restored statistical efficiency and produced estimates with better precision (Table 5) .
DISCUSSION
This is a multisite study in the United States examining anti-HCV positivity in a large cohort of newly enrolled, previously undiagnosed adult primary care outpatients from different regions of the country. We found that over a 6-year period, 6.4% of tested patients were anti-HCV + . However, as the majority of patients were not tested, the observed prevalence was just above 0.5%. We estimated that the expected anti-HCV prevalence in this population could be as high as 2.9%, indicating that during the study period, >81% of anti-HCV + persons may have been undetected. The findings from this study are supported by previous research. Anti-HCV positivity among patients tested and the observed prevalence are comparable to results from Spradling et al, who used a similarly diverse population of patients with access to care: estimates for anti-HCV prevalence among patients tested and observed are 5.5% and 0.7%, respectively, when the data are restricted to patients with no history of HCV diagnosis [13] . Roblin et al also reported an anti-HCV positivity of 5.1% among patients tested and an overall observed prevalence of 0.2%, although the proportion of patients tested was considerably lower [12] . Southern et al [14] found a much higher prevalence of anti-HCV among patients tested (11.5%) and overall observed prevalence (4.6%), likely reflecting a higher local prevalence of HCV and HCV risk factors [26, 27] and a higher-thanaverage proportion of patients tested for anti-HCV of nearly 40% [14] . Our expected prevalence estimate can be reasonably compared to an estimate of 2.0% anti-HCV prevalence among US adults aged 20-70 years [18] , accounting for the fact that African Americans, a high-prevalence group, are substantially overrepresented in the outpatient primary care cohort used for the current study. Moreover, our finding that testing based on risks or medical indications in the clinical setting underestimates anti-HCV prevalence by 81% is within the range of earlier findings [12] [13] [14] . Notably, our data further suggest that anti-HCV prevalence may vary regionally in the United States (Table 2 ). This observation is supported by prevalence estimates from prior studies [14, 26, 28, 29] .
Our analysis also indicated that patients' birth year, history of IDU, and elevated ALT were significant correlates of anti-HCV positivity, as were black race, Hispanic ethnicity, single marital status, and male sex. History of IDU and elevated ALT as predictors of anti-HCV positivity are consistent with the data supporting risk-based testing recommendations [12, 14, 15, 30] . Race, ethnicity, sex, and marital status have also previously been associated with anti-HCV positivity or current HCV infection [1, 13, 14] . Nevertheless, the finding that 74% of the identified anti-HCV + patients were born from 1945 to 1965 provides additional data in support of recommendations by the CDC and the US Preventive Task Force [17, 20] for HCV testing in this birth cohort and confirms previous findings of the burden of prevalence in this cohort [13, 14, 19, 21] . This study has several strengths. The analysis of a large, demographically diverse, multisite, multiyear cohort of outpatient primary care patients representing different geographic regions of the country increases the potential generalizability of the findings. Also, the use of multilevel modeling to adjust for correlation between patients within sites (healthcare centers) ensures that standard error estimates are conservative. Moreover, the use of multiple imputation to replace missing data restored statistical power and improved precision of estimates.
However, there are also some important limitations. First, blood transfusion before 1992, an important determinant of anti-HCV positivity among older adults, was not included in this analysis due to a lack of consistent data collection across sites. Second, it is likely that risk factors such as IDU were underreported [31] [32] [33] [34] [35] ; nondisclosure of relevant patient risk factors could lead to confounding of estimates [36] . Nonetheless, we determined that the proportions of patients identified as having history of IDU, hemophilia, HIV positivity, or elevated ALT were comparable to estimates reported in previous studies [12, 14, 16] . Third, cross-sectional analysis of this dataset limits our ability to assess temporal associations between independent risk factors and anti-HCV positivity; however, cross-sectional analysis was appropriate for other important objectives in this study such as estimates of anti-HCV prevalence and proportion of unidentified anti-HCV + persons. Fourth, it is likely that retrospective review of EMR did not adequately identify patients diagnosed with HCV outside participating health systems prior to their first encounter; patients with a previous HCV diagnosis who were misclassified at the first encounter would have been included in the study and may not have received additional HCV testing during the study. In addition, we were unable to identify patients diagnosed outside participating health systems during the study, and our estimate of unidentified anti-HCV + persons may be inflated as a result. Finally, in using multiple imputation to assign plausible values to missing data (sex, race/ethnicity, marital status, expected anti-HCV prevalence), we assumed that missing values were missing at random (eg, missing data values for sex or anti-HCV status are related conditionally to observed patient characteristics) [22, 23] . Despite our efforts to make this assumption more plausible [25, 37] by including a large number of relevant predictors in the imputation models, the assumption may not be fully met because there is a good likelihood that not all patient variables were observed. Still, others have noted that missing data originating from medical research are often related to observed patient data and that the missing-at-random assumption may be appropriate [22, 38] .
Despite these limitations, our findings demonstrate that testing based on risk and medical indications alone failed to identify four-fifths of previously undiagnosed adults with past exposure to HCV. This may be due in part to the difficulty in capturing complete patient risk history (eg, IDU) in EMRs to support the implementation of comprehensive risk-based HCV testing algorithms. HCV-infected persons who are not aware of their status cannot receive further clinical evaluation or antiviral treatment, and are unlikely to benefit from preventive services or secondary prevention recommendations (eg, reduction in alcohol use and other lifestyle changes) aimed at limiting disease progression and reducing liver-related morbidity and mortality [39, 40] . In the routine clinical environment, recent CDC and US Preventive Task Force recommendations to test patients born during 1945-1965 for HCV without the need for prior ascertainment of risk factors should be implemented [17, 20] . With the alignment of the risk-based and birth cohort testing recommendations, it is expected that identification of infected persons who were previously undiagnosed will increase, leading to higher rates of linkage to care and treatment as appropriate, or to programs that support linkage to care and treatment adherence, which would further result in reduced morbidity and mortality associated with HCV.
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